Therapy area located outside of head and neck;
Other skin diseases that might interfere with the efficacy evaluation;
Therapy area was previously received isotope or PDT or other treatment which might interfere with the efficacy evaluation;
Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution;
Scar diathesis;
Immunocompromised conditions;
Electrocardiographic abnormalities or organic heart diseases;
Coagulation disorders;
Hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase or total bilirubin > 1.5 upper limit of normal [ULN], or serum creatinine or blood urea nitrogen > 1.5 ULN);
Psychiatric diseases; Severe endocrinopathies;
Previous therapy of PWS within the last 4 weeks;
Participation in any clinical studies within the last 4 weeks;
Be judged not suitable to participate the study by the investigators

NCT03125057_exc_T2
Condition
skin diseases
NCT03125057_exc_T3
Qualifier
interfere with the efficacy evaluation
NCT03125057_exc_T4
Drug
isotope
NCT03125057_exc_T5
Drug
PDT
NCT03125057_exc_T6
Procedure
treatment
NCT03125057_exc_T7
Qualifier
might interfere with the efficacy evaluation
NCT03125057_exc_T8
Scope
isotope or PDT
NCT03125057_exc_T9
Condition
Allergy
NCT03125057_exc_T10
Drug
porphyrins
NCT03125057_exc_T11
Condition
Photosensitivity
NCT03125057_exc_T12
Drug
analogues
NCT03125057_exc_T13
Condition
Porphyria
NCT03125057_exc_T14
Condition
Allergic constitution
NCT03125057_exc_T15
Scope
porphyrins and analogues
NCT03125057_exc_T16
Condition
Scar diathesis
NCT03125057_exc_T17
Condition
Immunocompromised conditions
NCT03125057_exc_T18
Condition
Electrocardiographic abnormalities
NCT03125057_exc_T19
Qualifier
organic
NCT03125057_exc_T20
Condition
heart diseases
NCT03125057_exc_T21
Procedure
Electrocardiographic
NCT03125057_exc_T22
Condition
Coagulation disorders
NCT03125057_exc_T23
Measurement
or rena s abnorma
NCT03125057_exc_T24
Measurement
renal functions
NCT03125057_exc_T25
Value
abnormal
NCT03125057_exc_T26
Measurement
alanine aminotransferase
NCT03125057_exc_T27
Measurement
aspartate transaminase
NCT03125057_exc_T28
Measurement
total bilirubin
NCT03125057_exc_T29
Value
> 1.5 upper limit of normal [ULN]
NCT03125057_exc_T30
Scope
alanine aminotransferase or aspartate transaminase or total bilirubin
NCT03125057_exc_T31
Measurement
serum creatinine
NCT03125057_exc_T32
Measurement
blood urea nitrogen
NCT03125057_exc_T33
Value
> 1.5 ULN
NCT03125057_exc_T34
Scope
serum creatinine or blood urea nitrogen
NCT03125057_exc_T35
Scope
alanine aminotransferase or aspartate transaminase or total bilirubin > 1.5 upper limit of normal [ULN], or serum creatinine or blood urea nitrogen > 1.5 ULN
NCT03125057_exc_T36
Scope
Hepatic or renal functions abnormal
NCT03125057_exc_T37
Condition
Psychiatric diseases
NCT03125057_exc_T38
Qualifier
Severe
NCT03125057_exc_T39
Condition
endocrinopathies
NCT03125057_exc_T40
Temporal
Previous
NCT03125057_exc_T41
Procedure
therapy
NCT03125057_exc_T42
Temporal
within the last 4 weeks
NCT03125057_exc_T43
Observation
Participation in any clinical studies
NCT03125057_exc_T44
Temporal
within the last 4 weeks
NCT03125057_exc_T46
Condition
PWS